|
|
News Breaks | | | | December 13, 2012 | | 06:33 EDT |  | ONCY | Oncolytics Biotech announce positive top line Reolysindata for Phase III study
Oncolytics Biotech announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naive head and neck cancers. The endpoint examines initial percentage tumour changes between the pre-treatment and first post-treatment scans, typically performed at six weeks post-first treatment, of all patients enrolled in the study. The analysis was designed to assess early differences in response between loco-regional tumours and metastatic tumours, as classified and observed by the investigators. This is the first, and to this point only, endpoint to be un-blinded for this study. | |
|
News For ONCY From The Last 14 Days Check below for free stories on ONCY the last two weeks. |
|
|
| There are no results for ONCY |
|
|
|
|
|
|
